Boosting BioVersys’ R&D on anti-bacterial resistance drugs

Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is supporting the D-BSSE spin-off BioVersys with $8.92 Million to help the company develop first-in-class anti-virulence small molecule drugs designed to disarm bacteria, opening the door for a paradigm shift in the treatment of drug resistant bacterial infections. CARB-X is a global non-profit partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.